Investors focused on the Medical space have likely heard of Fibrocell Science , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Fibrocell Science is one of 847 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. FCSC is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for FCSC's full-year earnings has moved 57.09% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, FCSC has returned 52.67% so far this year. Meanwhile, the Medical sector has returned an average of 2.30% on a year-to-date basis. This means that Fibrocell Science is outperforming the sector as a whole this year.
Looking more specifically, FCSC belongs to the Medical - Biomedical and Genetics industry, which includes 353 individual stocks and currently sits at #55 in the Zacks Industry Rank. On average, stocks in this group have gained 3.54% this year, meaning that FCSC is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track FCSC. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Fibrocell Science , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Fibrocell Science is one of 847 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. FCSC is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for FCSC's full-year earnings has moved 57.09% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, FCSC has returned 52.67% so far this year. Meanwhile, the Medical sector has returned an average of 2.30% on a year-to-date basis. This means that Fibrocell Science is outperforming the sector as a whole this year.
Looking more specifically, FCSC belongs to the Medical - Biomedical and Genetics industry, which includes 353 individual stocks and currently sits at #55 in the Zacks Industry Rank. On average, stocks in this group have gained 3.54% this year, meaning that FCSC is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track FCSC. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>